免疫學領域的共同研究及授權契約:2016年～2025年

本報告提供了前所未有的途徑，可以全面了解世界領先的生物製藥公司簽署的免疫學相關合作和許可協議。

本報告提供了 2016 年至 2025 年 909 項免疫學相關交易的詳細資訊。提供雙方宣布的交易付款條款。這些數據為付款條款和其他貿易條款提供了有用的見解。

了解潛在合作夥伴談判交易條款的彈性，可以為談判過程提供重要的見解，讓您了解在談判條款時可以期望實現的目標。許多小型企業都希望有詳細的付款條款，但當涉及如何付款以及如何轉讓權利時，細節決定成敗。

本報告提供了當前協議交易和合作資料庫中記錄的自 2016 年以來宣布的合作和許可協議的綜合列表，以及可用的財務條款，以及公司及其合作夥伴向美國證券交易委員會提交的實際許可協議文件的在線副本鏈接。

報告的第一部分提供有關免疫學交易和商業活動的資訊。第1章對報告進行了介紹，第2章分析了免疫學領域的交易趨勢。

第 3 章介紹了免疫學領域已完成交易的財務條款和發展階段。交易按標題價值、預付款、里程碑付款和特許費率列出並分為幾個部分。

第 4 章回顧了在免疫學交易中最活躍的 25 家生物製藥公司。對於與美國證券交易委員會 (SEC) 公開宣布的協議交易，可以透過目前協議交易和聯盟資料庫中的連結在線存取。

第 5 章全面深入地回顧了 2016 年以來達成或宣布的免疫學交易，並提供合約文件。每個交易標題都透過網路連結連結到實際合約文件的線上版本，從而可以輕鬆根據需要存取每個合約文件。

第 6 章提供了按目標列出的免疫學病例綜合目錄。

該報告還包含大量圖表和圖形，重點介紹了自 2016 年以來的免疫學病例趨勢和活動。

此外，我們的綜合貿易目錄按公司 A-Z 和技術類型進行組織。每個交易標題都提供了一個指向在線交易記錄的網絡鏈接，並在可用的情況下提供合同文件，從而允許根據需要輕鬆訪問每個文件。

主要優點

免疫學合作與授權協議為讀者提供以下主要優勢：

• 了解 2016 年以來的合約趨勢
• 查看免疫學合作與許可機會
• 基準分析 - 確定交易的市場價值
• 財務條款 – 預付款、里程碑付款、特許權使用費
• 按公司 A-Z、治療和技術類型劃分的貿易目錄
• 大額交易金額
• 最活躍的交易者
• 確定每筆交易的資產和條款
• 查閱合約文件－洞察交易結構
• 盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性。
• 節省數百小時的研究時間

研究範圍

• 免疫學合作與授權交易旨在讓全球領先的生物製藥公司更深入地了解免疫學趨勢和交易結構。

回報內容

• 生物製藥產業免疫學相關交易的趨勢
• 合作與授權協議架構概述
• 免疫學領域交易記錄目錄，涵蓋製藥和生物技術
• 重要的免疫學交易
• 最活躍的免疫學許可公司

目錄

摘要整理

第1章 簡介

第2章 免疫學的交易趨勢

• 簡介
• 多年的免疫學的聯盟
• 各交易類型免疫學領域的聯盟
• 各業界的免疫學領域的聯盟
• 各開發階段的免疫學的聯合
• 各技術類型的免疫學領域的聯盟
• 各治療適應症的免疫學領域的聯盟

第3章 免疫學領域的聯盟的金融交易條件

• 簡介
• 公開免疫學領域的聯盟相關財務條件
• 免疫學領域的聯盟的主要價值
• 免疫學領域的交易的預付款
• 免疫學領域的交易的里程金
• 免疫學的特許權率

第4章 主要免疫學領域的交易和交易廠商

• 簡介
• 在免疫學合作方面最活躍的公司
• 免疫學領域最活躍的交易者名單
• 各價值排序的頂級免疫學交易

第5章 免疫學契約文件名錄

• 簡介
• 免疫學領域的合作協議，可提供合約

第6章 按治療標的免疫學領域的交易

• 簡介
• 按免疫治療標的交易
• 交易名錄
• 交易目錄 - 免疫學交易（按公司劃分），2016 年至 2025 年
• 交易清單 - 免疫學交易（按技術類型劃分）（2016 年至 2025 年）
• 定義交易類型
• 關於 Biopharma Research Ltd
• 當前合作夥伴關係
• 當前合約
• Current Partnering 的最新報告標題

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 909 immunology deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of immunology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse immunology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Immunology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of immunology trends and structure of deals entered into by leading biopharma companies worldwide.

Immunology Collaboration and Licensing Deals includes:

• Trends in immunology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of immunology deal records covering pharmaceutical and biotechnology
• The leading immunology deals by value
• Most active immunology licensing dealmakers

In Immunology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Immunology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

• 2.1. Introduction
• 2.2. Immunology partnering over the years
• 2.3. Immunology partnering by deal type
• 2.4. Immunology partnering by industry sector
• 2.5. Immunology partnering by stage of development
• 2.6. Immunology partnering by technology type
• 2.7. Immunology partnering by therapeutic indication

Chapter 3 - Financial deal terms for immunology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for immunology partnering
• 3.3. Immunology partnering headline values
• 3.4. Immunology deal upfront payments
• 3.5. Immunology deal milestone payments
• 3.6. Immunology royalty rates

Chapter 4 - Leading immunology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in immunology partnering
• 4.3. List of most active dealmakers in immunology
• 4.4. Top immunology deals by value

Chapter 5 - Immunology contract document directory

• 5.1. Introduction
• 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by immunology therapeutic target
• Deal directory
• Deal directory - Immunology deals by company A-Z 2016 to 2025
• Deal directory - Immunology deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Immunology partnering since 2016
• Figure 2: Immunology partnering by deal type since 2016
• Figure 3: Immunology partnering by industry sector since 2016
• Figure 4: Immunology partnering by stage of development since 2016
• Figure 5: Immunology partnering by technology type since 2016
• Figure 6: Immunology partnering by indication since 2016
• Figure 7: Immunology deals with a headline value
• Figure 8: Immunology deals with upfront payment values
• Figure 9: Immunology deals with milestone payment
• Figure 10: Immunology deals with royalty rates
• Figure 11: Active immunology dealmaking activity since 2016
• Figure 12: Top immunology deals by value since 2016